ada standards of care 2025 glp-1 receptor agonists recommendations in Diabetes Guidelines Must read for all doctors ▪️ Cardiovascular risk: Use RA or SGLT2 inhibitors for glycemic control & cardiovascular risk reduction. ▪️ Heart failure: Updates from the 2025 American
Description
22, 2025, when the U.S Food and Drug Administration (FDA) approved oral Wegovy by Novo Nordisk as the first daily, oral GLP-1 pill for weight management.
Federal regulators have approved the GLP-1 tablet Foundayo for weight loss
Ozempic and Wegovy users focus on nausea and vomiting
Previously we have shown that GLP-1 activates afferent renal nerve to increase efferent renal sympathetic nerve activity that negates the diuresis and natriuresis as a negative feedback mechanism in normal rats
Purpose of the Review Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management
They stand up to any scientific scrutiny
